Clinical pharmacology of selective COX-2 inhibitors.

@article{Capone2003ClinicalPO,
  title={Clinical pharmacology of selective COX-2 inhibitors.},
  author={Marta L Capone and Stefania Tacconelli and Maria Gina Sciulli and Paola Patrignani},
  journal={International journal of immunopathology and pharmacology},
  year={2003},
  volume={16 2 Suppl},
  pages={49-58}
}
The discovery of cyclooxygenase (COX)-2 has provided the rationale for the development of a new class of nonsteroidal antiinflammatory drugs (NSAIDs), the selective COX-2 inhibitors (denominated coxibs), with the aim of reducing the gastrointestinal (GI) toxicity associated with the administration of NSAIDs by virtue of COX-1 sparing. Rofecoxib and celecoxib are the first selective COX-2 inhibitors approved by the FDA and EMEA for the treatment of rheumatoid arthritis (RA), osteoarthritis (OA… CONTINUE READING
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…